Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that company management will present and host one-on-one meetings during the Stifel 2024 Virtual CNS Days taking place March 19 to 20, 2024.

Stifel 2024 Virtual CNS Days

  • Shawn Singh, Chief Executive Officer, will participate in a fireside chat on Wednesday, March 20 at 12:00 p.m. Eastern Time.

A webcast will be accessible through the “Events” page in the “Investors” section of the Company’s website at www.Vistagen.com. Investors interested in arranging a one-on-one meeting during the conference should contact their Stifel representative.

About Vistagen

Vistagen (Nasdaq: VTGN) is a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders. Five of Vistagen’s clinical-stage neuroscience pipeline candidates belong to a new class of drugs known as pherines, which are investigational neuroactive nasal sprays with innovative proposed mechanisms of action that activate chemosensory neurons in the nasal passages to impact fundamental neural circuitry in the brain without the need for systemic absorption or binding to receptors in the brain. Vistagen’s sixth investigational candidate is an oral prodrug with potential to inhibit, but not block, NMDA receptor activity. At Vistagen, we are passionate about delivering differentiated treatments that set new standards of care for people living with anxiety, depression, and other neurological disorders. Connect at www.Vistagen.com.

Investors: Mark A. McPartland (650) 577-3606 markmcp@vistagen.com

Media: Caren Scannell (650) 577-3601 cscannell@vistagen.com

Grafico Azioni Vistagen Therapeutics (NASDAQ:VTGN)
Storico
Da Dic 2024 a Gen 2025 Clicca qui per i Grafici di Vistagen Therapeutics
Grafico Azioni Vistagen Therapeutics (NASDAQ:VTGN)
Storico
Da Gen 2024 a Gen 2025 Clicca qui per i Grafici di Vistagen Therapeutics